Together, these results show that effective low-dose Anlotinib combined with anti-PD-1 therapy induces tumor vascular normalization and increases the proportions of CD4+ T, CD8+ T, and NK cells in EO771 breast tumors, which may, in turn, contribute to enhanced antitumor effects. The gene discussed is CD8A; the disease is breast neoplasm.